Aripiprazole IM Depot for Chinese Patients With Schizophrenia

Phase 1 Completed 24 enrolled Otsuka Beijing Research Institute

Non-randomizedParallel-groupOpen-labelOther

Summary

This study assess pharmacokinetics and safety of single-administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg in patients with schizophrenia.

Timeline

Start: 2017-06-23
Primary completion: 2019-11-08
Completion: 2019-11-08

Publications

Dong F, Wang F, Yuan X, Zhai Y, Uki M, Jiang T, Li A. Single- and multiple-dose pharmacokinetics, safety, and tolerability of Aripiprazole once-monthly, long-acting intramuscular injection for Chinese adults with schizophrenia. BMC Psychiatry. 2025 Oct 1;25(1):912. doi: 10.1186/s12888-025-07407-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aripiprazole	Other / unclassified	300 mg	Intramuscular
Subject	Aripiprazole	Other / unclassified	400 mg	Intramuscular

Aripiprazole IM Depot for Chinese Patients With Schizophrenia

Summary

Timeline

Publications

Drugs

Indications